FIELD: chemistry.
SUBSTANCE: invention relates to a solid form of compound of formula I-1, where form is crystalline Compound I-1· hydrate I, characterized by peaks expressed in units of 2 theta ±0.2, at approximately 6.5, 12.5, 13.7, 18.8 and 26.0 degrees on X-ray powder diffraction pattern obtained using Cu K alpha radiation; or where form is crystalline Compound I-1· anhydrous form A, characterized by peaks expressed in units of 2 theta ±0.2, approximately at 6.1, 12.2, 14.5, 22.3 and 31.8 degrees on X-ray powder diffraction pattern obtained using Cu K alpha radiation; or where form is crystalline Compound I-1· anhydrous form B, characterized by peaks expressed in units of 2 theta ±0.2, approximately at 7.2, 8.3, 12.9, 19.5 and 26.6 degrees on X-ray powder diffraction pattern obtained using Cu K alpha radiation; or where form is crystalline Compound I-1· anhydrous form C, characterized by peaks expressed in units of 2 theta ±0.2, at approximately 6.8, 13.4, 15.9, 30.9 and 32.9 degrees on X-ray powder diffraction pattern obtained using Cu K alpha radiation; or where form is crystalline Compound I-1· DMSO solvate characterized by peaks expressed in 2 theta units ±0.2, at about 8.9, 14.8, 16.5, 18.6, 20.9, 22.2 and 23.4 degrees on X-ray powder diffraction pattern obtained using Cu K alpha radiation; or where form is crystalline Compound I-1· DMAC solvate, characterized by peaks expressed in 2 theta units ±0.2, at about 6.0, 15.5, 17.7, 18.1, 20.4 and 26.6 degrees in X-ray powder diffraction X-ray powder pattern obtained using Cu Q alpha radiation; or where form is crystalline Compound I-1· acetone solvate, characterized by peaks expressed in units of 2 theta ±0.2, at approximately 8.9, 15.5, 15.8, 16.7, 22.3, 25.7 and 29.0 degrees on X-ray powder diffraction pattern obtained using Cu K alpha radiation; or where form is crystalline Compound I-1· isopropanol solvate, characterized by peaks expressed in units of 2 theta ±0.2, at approximately 6.9, 17.1, 17.2, 19.1, 19.6, 23.7, 24.4 and 28.9 degrees on X-ray powder diffraction pattern obtained using Cu K alpha radiation. Invention also relates to a method of producing compound I-1 of anhydrous form A and to a composition having inhibitory activity on ATR kinase based on said compound.
.
EFFECT: technical result is obtaining a new compound and its crystalline forms, as well as a composition based thereon, which can be used in medicine for treating cancer diseases.
59 cl, 44 dwg, 12 tbl, 19 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PRODUCING ATR KINASE INHIBITORS (EMBODIMENTS) | 2014 |
|
RU2720408C2 |
| COMPOUNDS APPLICABLE AS ATR KINASE INHIBITORS | 2020 |
|
RU2750148C1 |
| PROCESSES FOR MAKING COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | 2012 |
|
RU2677292C2 |
| PYRIDO[1,2-A]PYRIMIDONE ANALOG, ITS CRYSTAL FORM, ITS INTERMEDIATE COMPOUND AND METHOD FOR THEIR PREPARATION | 2016 |
|
RU2753696C2 |
| INDASOLE INHIBITORS OF Wnt SIGNAL PATH AND THEIR THERAPEUTIC APPLICATIONS | 2013 |
|
RU2638932C2 |
| INTEGRATED STRESS PATHWAY PRODRUG MODULATORS | 2019 |
|
RU2824500C2 |
| NEW METHOD FOR SYNTHESIS OF PHENOXYDIAMINOPYRIMIDINE COMPOUND | 2019 |
|
RU2805661C2 |
| CRYSTAL FORMS OF TRIAZOLOPYRIMIDINE COMPOUND | 2017 |
|
RU2754856C2 |
| SOLID FORMS OF 3-(5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS AND USE | 2012 |
|
RU2611007C2 |
| COMPOUNDS AND METHODS FOR INHIBITING JAK | 2016 |
|
RU2760359C2 |
